INCYTE CORP

Incyte partners for exclusive AML therapy in China, expanding oncology reach and delivering targeted treatment to high‑risk leukemia patients.

Incyte reveals breakthrough Phase‑1 oncology data at ESMO 2026 and partners with Halozyme to develop subcutaneous delivery of INCA033989, boosting patient access.

Incyte’s EU approval of Opzelura, the first steroid‑free JAK inhibitor for eczema, boosts shares 7%, signaling a new biotech surge and a breakthrough skin‑care option.

Incyte boosts its oncology pipeline with a $200 M AI push, partnering with Genesis and Edison Scientific’s Kosmos to speed drug discovery and potentially lift shares.

Incyte shares 54‑week Phase‑3 STOP‑HS data on povorcitinib, revealing longer‑term efficacy and safety for hidradenitis suppurativa at AAD 2026.

Incyte’s $35 million option for Prelude’s mutant‑selective JAK2V617F inhibitor could accelerate its MPN pipeline, boost precision oncology, and lift shares to a new 52‑week high.

Incyte Corporation’s povorcitinib, a small-molecule JAK1/2 inhibitor, has shown promising 24-week efficacy data in treating hidradenitis suppurativa, potentially positioning the company for significant growth and a regulatory submission in the US la…

Incyte Corp’s Q2 earnings exceeded expectations, with a net income of $405 million and a 16% revenue increase, driven by strong demand for its key product Jakafi.

Incyte Corporation has appointed Bill Meury as its new CEO, sparking a 4.18% rise in stock price and investor optimism for new strategic directions.

Incyte Corp reports strong Q1 2025 performance, exceeding revenue estimates and raising revenue guidance for its flagship product Jakafi to $3 billion.